Loading…
Loading…
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 1,885 put options on the stock. This represents an increase of 1,101% compared to the average volume of 157 put options. Evelo Biosciences Stock Performance Evelo Biosciences has a 1 year low of $0.00 and
Profitability This table compares Silverback Therapeutics and Evelo Biosciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Evelo Biosciences N/A N/A N/A Valuation and Earnings This table compares Silverback Therapeutics and Evelo Biosciences"s top-line revenue, earnings per share (EPS) and valuation.
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors acquired 1,885 put options on the company. This represents an increase of approximately 1,101% compared to the typical daily volume of 157 put options. Evelo Biosciences Stock Down 50.0% Evelo Biosciences stock opened at $0.00
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of some unusual options trading on Wednesday. Traders acquired 1,885 put options on the stock. This is an increase of 1,101% compared to the average daily volume of 157 put options. Evelo Biosciences Trading Down 80.0% NASDAQ: EVLO opened at $0.00 on Thursday. The company
Insider and Institutional Ownership 44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 1,885 put options on the company. This is an increase of approximately 1,101% compared to the typical volume of 157 put options. Evelo Biosciences Stock Performance NASDAQ: EVLO opened at $0.00 on Thursday. The
Valuation and Earnings This table compares Antibe Therapeutics and Evelo Biosciences"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Antibe Therapeutics $7.51 million 0.00 -$14.54 million ($0.60) N/A Evelo Biosciences N/A N/A -$114.53 million ($13.01) 0.00 Antibe Therapeutics has higher revenue and earnings than
MONTRÉAL--(BUSINESS WIRE)--EVLO Energy Storage Inc. (EVLO), a fully integrated battery energy storage systems (BESS) provider and wholly owned subsidiary of Hydro-Québec, announces a major achievement in its relationship with investor-owned utility Dominion Energy (Dominion) to develop a battery energy storage system (BESS) with enhanced fire and safety features that meet and exceed Dominion's unique safety specifications. The augmented version of EVLOFLEX now has achieved UL 9540 certification.
No recent filings indexed.